Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP/DAP: Quetiapine for Agitation/Psychosis in Dementia/Parkinsonism
NCT00043849Phase 4
Key facts
- Status
- Completed
- Start
- Jul 2002
- Primary completion
- Jun 2005
- Countries
- 1
- Sponsor
- National Institute on Aging
- Modality
- Small Molecules
- Drugs
- quetiapine
- Conditions
- psychosisagitation
01
Overview
Phase 4, randomised, double-blind trial in psychosis and agitation comparing Quetiapine with Placebo (2 arms). Primary endpoints: Efficacy of quetiapine for the treatment of psychosis and/or agitation at 10 weeks and Safety and tolerability of quetiapine at 10 weeks. Started Jul 2002; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Quetiapine
Atypical antipsychotic (QUET)
Placebo
Matching placebo
03
Who it enrols
Patients with probable Alzheimer's disease, dementia with Lewy bodies, or Parkinson's disease with dementia, experiencing psychosis and/or agitation, with coexisting extrapyramidal motor features.
04
Endpoints
Primary
Efficacy of quetiapine for the treatment of psychosis and/or agitation
Safety and tolerability of quetiapine
Secondary
Influence on parkinsonism (motor function)
Beyond the preview
Go deeper on NCT00043849.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043849.